Press release

Zur Rose-Group acquires mail-order pharmacy Vitalsana

Zur Rose Group AG is taking over the mail-order pharmacy Vitalsana B.V. in Heerlen, as well as the associated service provider ApDG GmbH in Ulm, from Ströer SE & Co. KGaA. As Europe's leading mail-order pharmacy, the Group is thus underpinning its strategy oriented towards long-term growth. In the context of this acquisition, it is pooling a significant proportion of its mail-order business in the Aachen/Heerlen euro-region and achieving synergy effects along the entire value chain. With its mail-order pharmacy primarily geared towards non-prescription drugs, Vitalsana generated revenue of around EUR 30 million in 2016. The transaction is subject to approval by the responsible competition authorities. It has been agreed not to disclose any financial aspects.

The Zur Rose subsidiary DocMorris in Heerlen and the media company Ströer will also enter into a strategic partnership, which will contribute further to the growth of DocMorris. The mail-order pharmacy will continue the successful marketing model of Vitalsana, still relying on the wide-ranging media offerings, performance marketing options and data-focused products of Ströer. As a leading digital multi-channel media company in Europe, Ströer sets pioneering standards in terms of innovation, quality and targeted marketing.

Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail: ir@zurrose.com, telephone: +41 52 724 00 64

Media contact
Lisa Lüthi, Head of Corporate Communications
e-mail: lisa.luethi@zurrose.com, telephone: +41 52 724 08 14

Zur Rose Group
Operating under the "Zur Rose" and "DocMorris" brands, the Swiss-based Zur Rose Group is Europe's largest online pharmacy and one of Switzerland's leading wholesale suppliers to medical doctors. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care, while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders.

Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. In Germany and Austria, the Group operates through subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany). Furthermore, it holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 800 people at its various locations, Zur Rose Group generated revenue of CHF 880 million in 2016.

Zur Rose Group AG's shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX Swiss Exchange in accordance with the International Reporting Standard of SIX Swiss Exchange. The corporate bond issued in November 2012 for the purpose of financing the DocMorris acquisition is listed on the SIX Swiss Exchange (Swiss security no. 19972936, ISIN CH0199729366, ticker symbol ZRO12). zurrosegroup.com